Pfizer Inc.'s consumer business, says CEO Ian Read, provides the best shareholder value as a part of the firm, while market analysts expect Pfizer is preparing to split off the division along with its vaccines and oncology units.
Driven by US sales of the proton pump inhibitor Nexium 24HR (esomeprazole/20mg) and Advil (ibuprofen) analgesics, Pfizer's fiscal 2016 first-quarter consumer product revenues increased 2% to $822m, the firm said...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?